Research Article
No access
Published Online: 13 October 2015

Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements

Publication: Alternative and Complementary Therapies
Volume 21, Issue Number 5

Abstract

As the leading cause of death worldwide, cardiovascular disease has several modifiable risk factors, specifically dyslipidemia. Statin therapy has long been the mainstay treatment for dyslipidemia and has been demonstrated in various clinical trials to produce significant reductions in both major cardiovascular events and all-cause mortality. Given the changes per the 2013 American College of Cardiology/American Heart Association guidelines on the treatment of cholesterol, it is estimated that even more people now qualify for statin therapy. This can be problematic, as there is a sizeable population of patients whom are either statin-intolerant or prefer an alternative approach. The aim of this review is to describe the clinical trial data evaluating over-the-counter supplements including garlic (Allium sativum), green tea (Camellia sinensis) extract, guggul, red yeast (Monascus purpureus) rice, and niacin as alternative therapies for treating dyslipidemia. Research from current trials has shown that these supplements improve lipid profiles; however additional studies are needed to better establish their safety and clinical efficacy.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Laslett LJ, Alagona P, Clark BA, et al. The worldwide environment of cardiovascular disease: Prevalence, diagnosis, therapy, and policy issues. A report from the American College of Cardiology. J Am Coll Cardiol 2012;60(25suppl):S1–S49.
2.
Toth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006. J Clin Lipidol 2012;6:325–330.
3.
Medscape. New Guidelines Extend Statins to 13M More Americans. March 19, 2014. Online document at: www.medscape.com/viewarticle/822210 Accessed September 14, 2014.
4.
Ridker PM, Danielson E, Francisco FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–2207.
5.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002;360:7–22.
6.
Pfeffer MA, Sacks FM, Moyé LA, et al. Cholesterol and Recurrent Events: A secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995;76:98C–106C.
7.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001–1009.
8.
Bellosta S, Paoletti R, Corsini A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004;109(23suppl1):III50–III57.
9.
Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J Endocrinol Metab 2013;17:977–982.
10.
Gebhardt R. Multiple inhibitory effects of garlic extracts on cholesterol biosynthesis in hepatocytes. Lipids 1993;28:613–619.
11.
Warshafsky S, Kramer RS, Sivak SL. Effect of garlic on total serum cholesterol: A meta-analysis. Ann Intern Med 1993;119:599–605.
12.
Gardner CD, Chatterjee LM, Carlson JJ. The effect of a garlic preparation on plasma lipid levels in moderately hypercholesterolemic adults. Atherosclerosis 2001;154:213–220.
13.
Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: A randomized clinical trial. Arch Intern Med 2007;167:346–353.
14.
Sobenin IA, Pryanishnikov VV, Kunnova LM, et al. The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease. Lipids Health Dis 2010;9:119.
15.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Münster (PROCAM) Study. Circulation 2002;105:310–315;erratum in Circulation 2002;105:900.
16.
Sobenin IA, Andrianova IV, Demidova ON, et al. Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study. J Atheroscler Thromb 2008;15:334–338.
17.
Jung ES, Park SH, Choi EK, et al. Reduction of blood lipid parameters by a 12-wk supplementation of aged black garlic: A randomized controlled trial. Nutrition 2014;30:1034–1039.
18.
Maron DJ, Lu GP, Cai NS, et al. Cholesterol-Lowering effect of a theaflavin-enriched green tea extract: A randomized controlled trial. Arch Intern Med 2003;163:1448–1453.
19.
Ikeda I, Imasato Y, Sasaki E, et al. Tea catechins decrease micellar solubility and intestinal absorption of cholesterol in rats. Biochim Biophys Acta 1992;1127:141–146.
20.
Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: The Ohsaki study. JAMA 2006;296:1255–1265.
21.
Bogdanski P, Suliburska J, Szulinska M, et al. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res 2012;32:421–427.
22.
Nagao T, Hase T, Tokimitsu I. A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 2007;15:1473–1483.
23.
Batista GA, Cunha CL, Scartezini M, et al. Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias. Arq Bras Cardiol 2009;93:128–134.
24.
Basu A, Sanchez K, Leyva MJ, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr 2010;29:31–40.
25.
Di Pierro F, Menghi AB, Barreca A, et al. Greenselect Phytosome as an adjunct to a low-calorie diet for treatment of obesity: A clinical trial. Altern Med Rev 2009;14:154–160.
26.
Hsu CH, Tsai TH, Kao YH, et al. Effect of green tea extract on obese women: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr 2008;27:363–370.
27.
Deng R. Therapeutic effects of guggul and its constituent guggulsterone: Cardiovascular benefits. Cardiovasc Drug Rev 2007;25:375–390.
28.
Verma SK, Bordia A. Effect of Commiphora mukul (gum guggulu) in patients of [sic] hyperlipidemia with special reference to HDL-cholesterol. Indian J Med Res 1988;87:356–360.
29.
Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994;8:659–664.
30.
Nityanand S, Srivastava JS, Asthana OP. Clinical trials with gugulipid: A new hypolipidaemic agent. J Assoc Physicians India 1989;37:323–328.
31.
Szapary PO, Wolfe ML, Bloedon LT, et al. Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA 2003;290:765–772.
32.
Nohr LA, Rasmussen LB, Straand J. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complement Ther Med 2009;17:16–22.
33.
Gordon RY, Becker DJ. The role of red yeast rice for the physician. Curr Atheroscler Rep 2011;13:73–80.
34.
Gordon RY, Cooperman T, Obermeyer W, et al. Marked variability of monacolin levels in commercialized red yeast rice products: Buyer beware! Arch Intern Med 2010;170:1722–1727.
35.
Bogsrud MP, Ose L, Langslet G, et al. HypoCol (red yeast rice) lowers plasma cholesterol: A randomized placebo controlled study. Scand Cardiovasc J 2010;44:197–200.
36.
Cicero AF, Derosa G, Parini A, et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 2013;33:622–628.
37.
Verhoeven V, Lopez Hartmann M, Remmen R, et al. Red yeast rice lowers cholesterol in physicians—a double blind, placebo controlled randomized trial. BMC Complement Altern Med 2013;13:178.
38.
National Lipid Association. Red Yeast Rice Study Not Conclusive: An NLA Statement to Members. July 1, 2008. Online document at www.lipid.org/node/67 Accessed July 6, 2014.
39.
Zhao SP, Liu L, Cheng YC, Li YL. Effect of Xuezhikang, a Cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart disease. Atherosclerosis 2003;168:375–380.
40.
Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem 2003;49:1347–1352.
41.
Huang CF, Li TC, Lin CC, et al. Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients. Eur J Cardiovasc Prev Rehabil 2007;14:438–440.
42.
Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689–1693.
43.
Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: A meta-analysis of randomized controlled trials. Chin Med 2006;1:4.
44.
Heber D, Yip I, Ashley JM, et al. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 1999;69:231–236.
45.
Karl M, Rubenstein M, Rudnick C, Brejda J. A multicenter study of nutraceutical drinks for cholesterol: Evaluating effectiveness and tolerability. J Clin Lipidol 2012;6:150–158.
46.
Li JJ, Hu SS, Fang CH, et al. Effects of Xuezhikang, an extract of Cholestin, on lipid profile and C-reactive protein: A short-term time course in study in patients with stable angina. Clin Chim Acta 2005;352:217–224.
47.
Ogier N, Amiot MJ, Georgé S, et al. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr 2013;52:547–557.
48.
Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: A randomized trial. Ann Intern Med 2009;150:830–839.
49.
Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010;105:198–204.
50.
Keenan JM, Fontaine PL, Wenz JB, et al. Niacin revisited: A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424–1432.
51.
Ginsberg HN, Reyes-Soffer G. Niacin: A long history, but a questionable future. Curr Opin Lipidol 2013;24:475–479.
52.
Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol 2013:24:239–245.
53.
Blankenhorn DH, Johnson RL, Nessim SA, et al. The Cholesterol Lowering Atherosclerosis Study (CLAS): Design, methods, and baseline results. Control Clin Trials 1987;8:356–387.
54.
Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721–2726.
55.
AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255–2267.
56.
HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203–212.
57.
Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245–1255.
58.
Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723–726.
59.
Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT Study. A randomized trial. JAMA 2000;284:1263–1270.
60.
Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol 1997;79:1298–1301.
61.
Keenan JM, Wenz JB, Ripsin CM, et al. A clinical trial of oat bran and niacin in the treatment of hyperlipidemia. J Fam Pract 1992;34:313–319.
62.
Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959–1970.
63.
Bays HE, Shah A, Lin J, et al. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol 2010;4:515–521.
64.
Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353–361.
65.
Medscape. NIH Pulls Plug on AIM-HIGH Trial with Niacin. May 26, 2011. Online document at: www.medscape.com/viewarticle/743456 Accessed August 13, 2014.

Information & Authors

Information

Published In

cover image Alternative and Complementary Therapies
Alternative and Complementary Therapies
Volume 21Issue Number 5October 2015
Pages: 198 - 209

History

Published online: 13 October 2015
Published in print: October 2015
Published ahead of print: 10 August 2015

Permissions

Request permissions for this article.

Topics

    Authors

    Affiliations

    Disclosure Statement

    No competing financial interests exist.   ■

    Metrics & Citations

    Metrics

    Citations

    Export citation

    Select the format you want to export the citations of this publication.

    View Options

    Get Access

    Access content

    To read the fulltext, please use one of the options below to sign in or purchase access.

    Society Access

    If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

    Restore your content access

    Enter your email address to restore your content access:

    Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

    View options

    PDF/EPUB

    View PDF/ePub

    Full Text

    View Full Text

    Media

    Figures

    Other

    Tables

    Share

    Share

    Copy the content Link

    Share on social media

    Back to Top